Literature DB >> 19210692

Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept.

M Haidinger1, M Hecking, M Memarsadeghi, T Weichhart, J Werzowa, W H Hörl, M D Säemann.   

Abstract

Interference with T-cell function increases the risk of infections, especially during the early post-transplant period. Belatacept, a costimulation blocker, is currently being tested in phase III clinical trials. Here we report a renal transplant recipient who received belatacept and developed severe Pneumocystis jirovecii pneumonia (PCP) with fatal superinfections 4 years post transplant. Cytomegalovirus infection preceded PCP, which typically occurs in overimmunosuppressed patients, but has not yet been reported under T-cell costimulation blockade in transplant patients. This case illustrates the possibility of excessive immunosuppression even with a lymphocyte-specific regimen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19210692     DOI: 10.1111/j.1399-3062.2009.00366.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  7 in total

1.  Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii carriage in renal transplantation patients: a single-centre experience.

Authors:  Matthias Maruschke; Diana Riebold; Martha Charlotte Holtfreter; Martina Sombetzki; Steffen Mitzner; Micha Loebermann; Emil Christian Reisinger; Oliver W Hakenberg
Journal:  Wien Klin Wochenschr       Date:  2014-09-19       Impact factor: 1.704

Review 2.  Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.

Authors:  Gaurav Gupta; Karl L Womer
Journal:  Drug Des Devel Ther       Date:  2010-12-01       Impact factor: 4.162

3.  Genetic and Epidemiologic Analyses of an Outbreak of Pneumocystis jirovecii Pneumonia Among Kidney Transplant Recipients in the United States.

Authors:  Marwan M Azar; Elizabeth Cohen; Liang Ma; Ousmane H Cissé; Geliang Gan; Yanhong Deng; Kristen Belfield; William Asch; Matthew Grant; Shana Gleeson; Alan Koff; David C Gaston; Jeffrey Topal; Shelly Curran; Sanjay Kulkarni; Joseph A Kovacs; Maricar Malinis
Journal:  Clin Infect Dis       Date:  2022-03-01       Impact factor: 9.079

4.  Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression.

Authors:  Ekkehard M Kasper; Jiri Bartek; Scott Johnson; Burkhard S Kasper; Martha Pavlakis; Michael Wong
Journal:  Surg Neurol Int       Date:  2011-06-09

5.  Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

Authors:  Hernán Trimarchi; Tatiana Rengel; José Andrews; Matías Paulero; Alejandro Iotti; Agustina Forastiero; Fernando Lombi; Vanesa Pomeranz; Mariano Forrester; Romina Iriarte; Iris Agorio
Journal:  J Nephropathol       Date:  2016-03-18

6.  [Infections in organ transplantations].

Authors:  D Theegarten; O Anhenn; K-D Müller
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

7.  A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection.

Authors:  Quentin Perrier; Antoine Portais; Florian Terrec; Yann Cerba; Thierry Romanet; Paolo Malvezzi; Pierrick Bedouch; Rachel Tetaz; Lionel Rostaing
Journal:  Case Rep Nephrol Dial       Date:  2021-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.